Company intelligence / Profile preview

CMP Development LLC

Ownership: Private
Development stage: Commercial

Overview

CMP Development LLC develops and commercializes small molecule drugs targeting a range of diseases including nervous system disorders, metabolic/endocrine diseases, infectious diseases, stroke, pulmonary arterial hypertension, and hypophosphatemia. Several products have achieved regulatory approval in the US and Australia. The company has at least one active clinical trial starting in June 2024.

Therapeutic areas: CardiovascularEndocrinologyNeurologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

potassium phosphates

Unknown

Partnerships

Not specified

Beyond the preview

Go deeper on CMP Development LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMP Development LLC.

Explore the full profile